Adjuvant treatment of high-risk adult soft tissue sarcomas

A survey by the Italian Sarcoma Group

Sergio Frustaci, Massimiliano Berretta, Alessandro Comandone, Ettore Bidoli, Antonino De Paoli, Franco Gherlinzoni, Tommaso De Pas, Enza Barbieri, Maurizio Pertici, Gaetano Apice, Piero Picci

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aims and background: After the first adjuvant study on adult soft tissue sarcomas was concluded, the participating institutions continued to select and treat patients according to that protocol. The aim of this study was to test the protocol reproducibility when applied as a standard practice. Methods: A call for retrospective data was launched in June 1999 (self-referral of consecutive unregistered patients); thereafter, a prospective follow-up was performed. The treatment regimen consisted of epirubicin (60 mg/m 2 days 1 and 2), ifosfamide (3 g/m 2/die for 3 days) and equimolar doses of 6-mercapto-ethansulfonate (MESNA), with 300 μg G-CSF administered subcutaneously from day +8 until recovery, every 3 weeks for a total of 5 cycles. Results: From November 1996 to June 1999, 55 high-risk, adult patients were treated. The average median dose intensity was 89% of the planned program. Grade 3-4 toxicities were leukopenia (49%), thrombocytopenia (14%), transfusion requiring anemia in 7 patients (16%), and alopecia in all patients (100%). After a median follow-up of 70 months, 23 patients (41.8%) relapsed and 19 died. Median disease-free, local disease-free and overall survival rates have not yet been reached. The disease-free survival rates at 2 and 4 years were 73% and 57%, respectively; the corresponding overall survival rates were 91% and 70%, respectively. Conclusions: The feasibility and reproducibility of the original protocol were confirmed, since disease-specific overall survival and disease-free survival rates at the same period of observation and with the same prolonged follow-up did not differ.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalTumori
Volume92
Issue number2
Publication statusPublished - Mar 2006

Fingerprint

Sarcoma
Survival Rate
Disease-Free Survival
Therapeutics
Epirubicin
Ifosfamide
Alopecia
Leukopenia
Granulocyte Colony-Stimulating Factor
Thrombocytopenia
Surveys and Questionnaires
Anemia
Referral and Consultation
Observation
Survival

Keywords

  • Adjuvant chemotherapy
  • Adult soft tissue sarcomas
  • Italian Sarcoma Group
  • Survey

ASJC Scopus subject areas

  • Cancer Research

Cite this

Adjuvant treatment of high-risk adult soft tissue sarcomas : A survey by the Italian Sarcoma Group. / Frustaci, Sergio; Berretta, Massimiliano; Comandone, Alessandro; Bidoli, Ettore; De Paoli, Antonino; Gherlinzoni, Franco; De Pas, Tommaso; Barbieri, Enza; Pertici, Maurizio; Apice, Gaetano; Picci, Piero.

In: Tumori, Vol. 92, No. 2, 03.2006, p. 92-97.

Research output: Contribution to journalArticle

Frustaci, S, Berretta, M, Comandone, A, Bidoli, E, De Paoli, A, Gherlinzoni, F, De Pas, T, Barbieri, E, Pertici, M, Apice, G & Picci, P 2006, 'Adjuvant treatment of high-risk adult soft tissue sarcomas: A survey by the Italian Sarcoma Group', Tumori, vol. 92, no. 2, pp. 92-97.
Frustaci, Sergio ; Berretta, Massimiliano ; Comandone, Alessandro ; Bidoli, Ettore ; De Paoli, Antonino ; Gherlinzoni, Franco ; De Pas, Tommaso ; Barbieri, Enza ; Pertici, Maurizio ; Apice, Gaetano ; Picci, Piero. / Adjuvant treatment of high-risk adult soft tissue sarcomas : A survey by the Italian Sarcoma Group. In: Tumori. 2006 ; Vol. 92, No. 2. pp. 92-97.
@article{4f90f627d5b4498ba23c7008cbb69dc6,
title = "Adjuvant treatment of high-risk adult soft tissue sarcomas: A survey by the Italian Sarcoma Group",
abstract = "Aims and background: After the first adjuvant study on adult soft tissue sarcomas was concluded, the participating institutions continued to select and treat patients according to that protocol. The aim of this study was to test the protocol reproducibility when applied as a standard practice. Methods: A call for retrospective data was launched in June 1999 (self-referral of consecutive unregistered patients); thereafter, a prospective follow-up was performed. The treatment regimen consisted of epirubicin (60 mg/m 2 days 1 and 2), ifosfamide (3 g/m 2/die for 3 days) and equimolar doses of 6-mercapto-ethansulfonate (MESNA), with 300 μg G-CSF administered subcutaneously from day +8 until recovery, every 3 weeks for a total of 5 cycles. Results: From November 1996 to June 1999, 55 high-risk, adult patients were treated. The average median dose intensity was 89{\%} of the planned program. Grade 3-4 toxicities were leukopenia (49{\%}), thrombocytopenia (14{\%}), transfusion requiring anemia in 7 patients (16{\%}), and alopecia in all patients (100{\%}). After a median follow-up of 70 months, 23 patients (41.8{\%}) relapsed and 19 died. Median disease-free, local disease-free and overall survival rates have not yet been reached. The disease-free survival rates at 2 and 4 years were 73{\%} and 57{\%}, respectively; the corresponding overall survival rates were 91{\%} and 70{\%}, respectively. Conclusions: The feasibility and reproducibility of the original protocol were confirmed, since disease-specific overall survival and disease-free survival rates at the same period of observation and with the same prolonged follow-up did not differ.",
keywords = "Adjuvant chemotherapy, Adult soft tissue sarcomas, Italian Sarcoma Group, Survey",
author = "Sergio Frustaci and Massimiliano Berretta and Alessandro Comandone and Ettore Bidoli and {De Paoli}, Antonino and Franco Gherlinzoni and {De Pas}, Tommaso and Enza Barbieri and Maurizio Pertici and Gaetano Apice and Piero Picci",
year = "2006",
month = "3",
language = "English",
volume = "92",
pages = "92--97",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Adjuvant treatment of high-risk adult soft tissue sarcomas

T2 - A survey by the Italian Sarcoma Group

AU - Frustaci, Sergio

AU - Berretta, Massimiliano

AU - Comandone, Alessandro

AU - Bidoli, Ettore

AU - De Paoli, Antonino

AU - Gherlinzoni, Franco

AU - De Pas, Tommaso

AU - Barbieri, Enza

AU - Pertici, Maurizio

AU - Apice, Gaetano

AU - Picci, Piero

PY - 2006/3

Y1 - 2006/3

N2 - Aims and background: After the first adjuvant study on adult soft tissue sarcomas was concluded, the participating institutions continued to select and treat patients according to that protocol. The aim of this study was to test the protocol reproducibility when applied as a standard practice. Methods: A call for retrospective data was launched in June 1999 (self-referral of consecutive unregistered patients); thereafter, a prospective follow-up was performed. The treatment regimen consisted of epirubicin (60 mg/m 2 days 1 and 2), ifosfamide (3 g/m 2/die for 3 days) and equimolar doses of 6-mercapto-ethansulfonate (MESNA), with 300 μg G-CSF administered subcutaneously from day +8 until recovery, every 3 weeks for a total of 5 cycles. Results: From November 1996 to June 1999, 55 high-risk, adult patients were treated. The average median dose intensity was 89% of the planned program. Grade 3-4 toxicities were leukopenia (49%), thrombocytopenia (14%), transfusion requiring anemia in 7 patients (16%), and alopecia in all patients (100%). After a median follow-up of 70 months, 23 patients (41.8%) relapsed and 19 died. Median disease-free, local disease-free and overall survival rates have not yet been reached. The disease-free survival rates at 2 and 4 years were 73% and 57%, respectively; the corresponding overall survival rates were 91% and 70%, respectively. Conclusions: The feasibility and reproducibility of the original protocol were confirmed, since disease-specific overall survival and disease-free survival rates at the same period of observation and with the same prolonged follow-up did not differ.

AB - Aims and background: After the first adjuvant study on adult soft tissue sarcomas was concluded, the participating institutions continued to select and treat patients according to that protocol. The aim of this study was to test the protocol reproducibility when applied as a standard practice. Methods: A call for retrospective data was launched in June 1999 (self-referral of consecutive unregistered patients); thereafter, a prospective follow-up was performed. The treatment regimen consisted of epirubicin (60 mg/m 2 days 1 and 2), ifosfamide (3 g/m 2/die for 3 days) and equimolar doses of 6-mercapto-ethansulfonate (MESNA), with 300 μg G-CSF administered subcutaneously from day +8 until recovery, every 3 weeks for a total of 5 cycles. Results: From November 1996 to June 1999, 55 high-risk, adult patients were treated. The average median dose intensity was 89% of the planned program. Grade 3-4 toxicities were leukopenia (49%), thrombocytopenia (14%), transfusion requiring anemia in 7 patients (16%), and alopecia in all patients (100%). After a median follow-up of 70 months, 23 patients (41.8%) relapsed and 19 died. Median disease-free, local disease-free and overall survival rates have not yet been reached. The disease-free survival rates at 2 and 4 years were 73% and 57%, respectively; the corresponding overall survival rates were 91% and 70%, respectively. Conclusions: The feasibility and reproducibility of the original protocol were confirmed, since disease-specific overall survival and disease-free survival rates at the same period of observation and with the same prolonged follow-up did not differ.

KW - Adjuvant chemotherapy

KW - Adult soft tissue sarcomas

KW - Italian Sarcoma Group

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=33744770580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744770580&partnerID=8YFLogxK

M3 - Article

VL - 92

SP - 92

EP - 97

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 2

ER -